192
A.R. Siedle et al. / Journal of Molecular Catalysis A: Chemical 214 (2004) 187–198
Table 3
Characterization data for ligands and metallocenesa
Flu-C2H4-flu (1): 1H NMR (CDCl3): 7.75 (d, 8), 7.37 (td, 8, 2), 7.30–7.29 (m), 3.83 (H9), 1.73 (CH2). 13C NMR: 146.7, 141.2 (Cipso), 126.8, 126.7,
124.0, 119.6, 46.9 (C9), 26.5 (CH2). Mass spectrum: m/z 358 (M+), 191 (C13H11+), 178 (C14H10+), mp 222–223 ◦C (xylenes), 36%.
Flu-C2H4-OSO2CF3 (2): 1H NMR (CDCl3): 7.81 (d,7, H4,5), 7.54 (dd, 8, 1, H1,8), 7.45 (t, 7, H3,6), 7.39 (td, 8, 1, H2,7), 4.41 (t, 7, CH2OSO2), 4.18
(t, 6, H9), 2.62 (td, 7, 6 CH2CH2OSO2). 13C NMR: 144.6, 140.8, 127.6, 127.2, 123.9, 120.1, 74.4 (CH2OSO2), 43.4 (C9), 32.1 (CH2CH2OSO2). 19F
NMR: −78.8.
Flu-C2H4-CPA (4): 1H NMR (CDCl3): 7.81 (s, H4∗,5∗), 7.80 (d, H3∗,6∗), 7.74 (dt, 7, 1, H4,5), 7.61 (dd, 8, 7, H2∗,7∗), 7.51 (d, 7, H1∗,8∗), 7.37 (dd, 7,
1, H1,8), 7.35 (tm, 7, H3,6), 7.28 (td, 7, 1, H2,7), 4.39 (t, 6, H9∗), 3.91 (t, 5, H9), 2.01 (m, CPA-CH2), 1.91 (m, Flu-CH2). 13C NMR: 146.7, 145.4,
141.2, 137.4, 127.7, 127.2, 126.9, 126.8, 125.2, 125.1, 122.8, 120.6, 119.7, 49.5 (C9), 47.0 (C9∗), 28.4 (CPA-CH2), 27.0 (flu-CH2). Mass spectrum:
m/z 382 (M+), 203 (C16H11+). mp 225–227 ◦C (heptane–toluene), 51%. Anal. C, 94.2 (94.1); H, 5.8 (5.9).
Flu-C2H4-H2CPA (5): 1H NMR (CDCl3): 7.73 (dt, 7, 1, H4,5), 7.39 (dq, 7, 1, H1,8), 7.35 (tdd, 7, 1, 0.6, H3,6), 7.28 (td, 8, 1, H2,7), 7.16 (m, 4H,
H2CPA), 7.08 (m, 2H, H2CPA), 3.92 and 3.91 (overlapping t, 2H, H9,9∗), 3.12 (m, 4H, H2CPA-H4,5), 2.01 (m, 2H, H2CPA-CH2), 1.72 (m, 2H,
flu-CH2). 13C NMR: 146.8, 144.1, 141.2, 138.5, 130.2, 127.2, 126.83, 126.79, 124.83, 124.16, 122.0, 119.7, 49.3 and 47.1 (H9,9∗), 28.6 (CH2), 27.1
(CH2), 26.0 (H2CPA CH2). Mass spectrum: m/z 384.1813 (M+, calcd. 384.1827), 206 (M+ − C14H10). mp 189–190 ◦C (CH2Cl2–acetone), 65%.
Anal. C, 93.8 (93.7); H, 6.2 (6.2).
Flu-C2H4-4,5-Me2-flu (6): 1H NMR (CDCl3): 7.66 (d, 8, H4,5), 7.28 (m, H3,6), 7.21–7.19 (m, H2,7, H1,8), 7.12 (t, 7, H2∗,7∗), 7.08 (d, 7, H1∗,8∗ or
H3∗,6∗), 7.02 (d, 7, H3∗,6∗ or H1∗,8∗), 3.71 and 3.67 (t, 5, H9 and H9∗), 2.67 (s, CH3), 1.61 (m, CH2), 1.50 (m, CH2). 13C NMR: 148.0, 146.8,
141.19, 141.16, 131.8, 130.6, 126.77, 126.74, 126.56, 124.1, 121.3, 119.6, 46.86 and 46.45 (C9,9∗), 26.9 and 25.6 (CH2), 25.3 (CH3). Mass
spectrum: m/z 386.2036 (M+, calcd. 386.2029). mp 173–175 ◦C (heptane), 57%. Anal. C, 92.8 (92.9); H, 7.2 (7.0).
Flu-C2H4-2,7-Cl2-flu (7): 1H NMR (CDCl3): 7.74 (d, 7, H4,5), 7.58 (d, 8, H4∗,5∗), 7.37 (t, 7, H3,6), 7.32 (m, H2,7 and H3∗,6∗), 7.27 (d, 8, H1,8), 7.19
(m, H1∗,8∗), 3.83 and 3.75 (H9 and H9∗), 1.64 and 1.58 (CH2). 13C NMR: 148.2, 146.2, 141.3, 138.8, 132.9, 127.4, 127.0, 126.9, 124.5, 124.0,
120.6, 119.7, 46.8 and 46.6 (C9,9∗), 25.9 and 25.7 (CH2). Mass spectrum: m/z 426.0964 (M+, calcd. 426.0937). mp 206–208 ◦C (toluene), 45%.
Anal. C, 78.7 (78.4); H, 4.7 (4.8).
Flu-C2H4-2,7-F2-flu (8): 1H NMR (CDCl3): 7.76 (d, 8, H4,5), 7.60 (dd, 8, 5 [4JHF], H4∗,5∗), 7.39 (td, 8, 2, H3,6), 7.32 (td, H2,7) overlapping 7.29 (m,
3
3
3
4
H
1,8), 7.06 (t, JHH and JHF = 9, m, H3∗,6∗), 6.94 (dd, JHH = 9, JHH = 2, H1∗,8∗), 3.88 (m, H9∗), 3.78 (m, H9), 1.67 and 1.54 (m, CH2). 13C
1
3
4
NMR: 162.2 (d, JCF = 245, H2∗,7∗), 148.6 (d, JCF = 10, H1∗,8∗), 146.2 (C1a,8a), 141.2 (C4a,5a), 136.4 (d, JCF = 2, C4a∗,5a∗), 126.9, 126.8, 123.9,
3
2
2
120.2 (d, JCF = 10, H4∗,5∗), 119.7, 114.1 (d, JCF = 23, C1∗,8∗ or C3∗,6∗), 111.4 (d, JCF = 23, C3∗,6∗ or C1∗,8∗), 49.93 and 49.60 (C9 and C9∗),
25.95 and 25.90 (CH2). 19F NMR: −116.2 (td, 9, 5). Mass spectrum: m/z 394.1472 (M+, calcd. 394.1526), 201 (C13H7F2+), 180 (C14H12+). mp
207–208 ◦C (toluene–hexane), (50%). Anal. C, 85.3 (85.5); H, 5.1 (5.3).
Flu-C2H4-4-Meflu (9): 1H NMR (CDCl3): 7.90 (d, 8, H5∗), 7.76 (d, 7, H4,5), 7.40–7.36 (m, 3H), 7.34–7.30 (m, 6H), 7.21 (t, 7, H2∗), 7.16 (t, 8, H2,7),
3.83 (2H, br, H9,9∗), 1.75–1.70 (m, 4H, CH2). 13C NMR: 147.07, 147.03, 146.69, 142.2, 141.2, 139.2, 132.8, 129.1, 126.78, 126.73, 126.70, 126.42,
126.05, 124.1, 123.9, 122.9, 121.5, 119.6, 46.89 and 46.65 (C9,9∗), 26.55 and 26.17 (CH2), 21.0 (CH3). Mass spectrum: m/z 372.1892 (M+, calcd.
372.1873), 192 (C15H12+), 178 (C14H10+), 165 (C13H9+). mp 194–195 ◦C (CH2Cl2–EtOH), 69%. Anal. C, 93.(93.4); H, 6.5 (6.8).
Flu-C2H4-4-i-Prflu (10): 1H NMR (CDCl3): 7.92 (d, 8, H5∗), 7.71 (d, 8, H4,5), 7.36–7.25 (m, 11H), 7.12 (d, 7, H3∗), 3.78 (m, H9,9∗ and CHCH3),
1.67 (m, CH2), 1.43, (d, 7, CH3), 1.37 (d, 7, CH3). 13C NMR: 147.34, 147.32, 146.7, 144.1, 141.57, 141.17, 141.16, 138.0, 126.77, 126.75, 126.71,
126.0, 124.06, 124.04, 123.9, 123.36, 123.15, 121.4, 119.6, 46.9 and 46.5 (C9,9∗), 29.4 (CHCH3), 26.61 and 26.16 (CH2), 22.92 and 22.57 (CH3).
Mass spectrum: m/z 400 (M+), 357 (M+ − C3H7). mp 115–117 ◦C (heptane), 65%. Anal. C, 93.0 (92.9); H, 7.0 (7.0).
Flu-C2H4-2,7-(p-tolyl)2-flu (11): 1H NMR (CDCl3): 7.80 (d, 8, H4∗5∗), 7.76 (d, 7, H4,5), 7.62 (dd, 8, 2, H3∗6∗), 7.56 (AAꢀXXꢀ pattern, d, 8, Htolyl
meta to CH3), 7.50 (s, H1∗,8∗), 7.35 (t, 7, H3,6), 7.30 (AAꢀXXꢀ pattern, d, 8, Htolyl ortho to CH3), 7.28 (d, 8, H1,8), 7.20 (td, 8, 1, H2,7), 3.92 and
3.84 (m, H9,9∗), 2.45 (s, CH3), 1.76 (m, CH2). 13C NMR: 147.5, 146.6, 141.2, 139.96, 139.66, 138.4, 136.8, 129.4, 126.87, 126.78, 126.77, 125.9,
124.1, 122.5, 119.89, 119.65, 46.91 and 46.78 (C9,9∗), 26.0 and 25.9 (CH2), 21.1 (CH3). Mass spectrum: m/z 538.2640 (M+, calcd. 538.2655). mp
242–243 ◦C (toluene), 70%. Anal. C, 93.7 (93.6); H, 6.3 (6.4).
Flu-C2H4-2,7-t-Bu2-flu (12): 1H NMR (CDCl3): 7.80 (d, 8, H4,5), 7.66 (d, 8, H4∗5∗), 7.41 (d, 7, H3∗,6∗), 7.40 (tm, 7, H3,6), 7.35 (s, H1∗8∗), 7.33 (t, 7,
H
2,7), 7.30 (d, 7, H1,8), 3.84 and 3.83 (t, H9 and H9∗), 1.67 (m, CH2), 1.41 (s, CH3). 13C NMR: 149.6, 146.86, 146.70, 141.3, 138.7, 126.79,
126.78, 123.76, 123.72, 120.8, 119.7, 118.9, 46.65 and 46.61 (C9,9∗), 34.8 (CCH3), 31.6 (CH3), 25.4 and 24.1 (CH2). Mass spectrum: m/z 470.2896
(M+, calcd. 470.2968), 413 (M+ − C4H9), 357 (m/z 413-C4H8). mp 227–228 ◦C (heptane), 70%. Anal. C, 91.9 (91.9); H, 8.1 (8.0).
Flu-C2H4-9-Mebenzo[c]flu (13): 1H NMR (CDCl3): 8.76 (d, 8, H1∗), 8.26 (d, 8, H11∗), 7.98 (d, 8, H4∗), 7.81 (d, 8, H5∗), 7.78 (d, 7, H4,5), 7.65 (ddd,
8, 7, 1, H2∗), 7.54 (td, 7, 1, H3∗), 7.46 (d, 8, H6∗), 7.40 (t, 7, H3,6), 7.34–7.24 (m, H2,7, H1,8 and H10∗), 7.18 (s, H8∗), 3.88 (t, 5, H7∗), 3.80 (t, 5,
H9), 2.50 (s, CH3), 1.75–1.65 (m, CH2 next to benzoflu), 1.53 (m, CH2 next to flu). 13C NMR: 147.9, 146.6, 145.2, 141.25, 141.21, 139.7, 135.83,
135.62, 133.4, 129.20, 129.01, 127.76, 127.24, 126.80, 126.76, 126.64, 126.25, 124.87, 124.67, 124.07, 123.7, 122.35, 122.13, 119.6, 46.87 and
46.82 (CHCH2), 25.65 and 25.62 (CH2), 21.48 (CH3). Mass spectrum: m/z 422 (M+), 229 (C15H13+), 257 (M+ − C13H9). mp 154.5–156 ◦C
(CH2Cl2–EtOH), 62%. Anal. C, 93.8 (93.6); H, 6.2 (6.3).
Flu-C2H4-2,7-t-Bu2-4-(␣-Np)flu (14): 1H NMR (CDCl3): 7.98 (m, 2H), 7.82 (m, 2H), 7.64–7.20 (m), 6.87 (dm, 8, 1, 1H), 6.13 (t, 9, 1H), 3.90 (m,
H9,9∗), 1.8–1.7 (m, CH2), 1.44 (s, CH3), 1.28 (s, CH3). 13C NMR: Over 43 peaks between 149.1 and 119.7 ppm, 46.77 and 46.69 (C9,9∗), 34.81 and
34.58 (CCH3), 31.60 and 31.43 (CH3), 25.85, 25.49, 25.32 and 25.17 (CH2). Mass spectrum: m/z 596.3513 (M+, calcd. 596.3438), 483, 305, 291.
Mp 115 ◦C (MeOH), 45%. Anal. C, 92.6 (92.4); H, 7.4 (7.4).
3
9,9ꢀ-(2,7-F2-flu)2 (15): 1H NMR (CD2Cl2): 7.53 (dd, 8, 5 [4JHF], H4,5), 7.00 (td, 9 (3JHH and JHF), 2 (4JHH), H3,6), 6.61 (br, H1,8), 4.66 (s, H9). 13C
NMR: 161.8 (d, 246 (1JCF), C2,7), 145.7 (d, 8 (3JCF), C1a,8a), 136.6 (s, C4a,5a), 120.5 (d, 9 (3JCF), C4,5), 114.9 (d, 23 (2JCF), C1,8 or C3,6), 111.3
(d, 23 (2JCF), C3,6 or C1,8), 49.5 (C9). 19F NMR: −115.3 (br). Mass spectrum: m/z 402 (M+), 201 (C13H7F2+). mp 233–234 ◦C (heptane), 40%.
Anal. C, 77.6 (77.9); H, 3.5 (3.6).